Thinking and memory in CAR-T cell therapy for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how CAR-T cell therapy for certain types of lymphoma may affect thinking and memory. It helps doctors understand and support patients' brain health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or a slow-growing lymphoma that has changed into a faster-growing type.
- You are getting CAR-T cell therapy that targets CD19 because your lymphoma came back or did not respond to other treatments.
- You are at least 18 years old when you were first diagnosed with lymphoma.
- Your lymphoma has not spread to your brain or spinal cord.
- You have not had radiation therapy to your brain or spinal cord.
- You do not have a serious psychiatric or brain disorder that would make it hard to assess thinking and memory.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
This study looks at how well long-term lymphoma survivors' thinking and memory are working. It is for people who are 3 to 5 years after finishing their first chemotherapy and are in remission. The goal is to understand how the treatment may have affected brain function.
This study looks at how thinking and brain function change over time in people with lymphoma who receive CAR T therapy. It may help doctors understand side effects and better support patients during and after treatment.
Hear when a new High-grade B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.